Louis Chesler
Louis Chesler
Verified email at - Homepage
Cited by
Cited by
Challenges to curing primary brain tumours
K Aldape, KM Brindle, L Chesler, R Chopra, A Gajjar, MR Gilbert, ...
Nature reviews Clinical oncology 16 (8), 509-520, 2019
Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.
OV Volpert, WF Ward, MW Lingen, L Chesler, DB Solt, MD Johnson, ...
The Journal of clinical investigation 98 (3), 671-679, 1996
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
MD Johnson, HRC Kim, L Chesler, G Tsao‐Wu, PJ Polverini, N Bouck
Journal of cellular physiology 160 (1), 194-202, 1994
Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease.
Y Vodovotz, MS Lucia, KC Flanders, L Chesler, QW Xie, TW Smith, ...
The Journal of experimental medicine 184 (4), 1425-1433, 1996
The ALKF1174L mutation potentiates the oncogenic activity of MYCN in neuroblastoma
T Berry, W Luther, N Bhatnagar, Y Jamin, E Poon, T Sanda, D Pei, ...
Cancer cell 22 (1), 117-130, 2012
Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma
M Brockmann, E Poon, T Berry, A Carstensen, HE Deubzer, L Rycak, ...
Cancer cell 24 (1), 75-89, 2013
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
L Chesler, C Schlieve, DD Goldenberg, A Kenney, G Kim, A McMillan, ...
Cancer research 66 (16), 8139-8146, 2006
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC
FJ Swartling, V Savov, AI Persson, J Chen, CS Hackett, PA Northcott, ...
Cancer cell 21 (5), 601-613, 2012
Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1
L Chesler, DW Golde, N Bersch, MD Johnson
Pleiotropic role for MYCN in medulloblastoma
FJ Swartling, MR Grimmer, CS Hackett, PA Northcott, QW Fan, ...
Genes & development 24 (10), 1059-1072, 2010
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease
RM Hill, S Kuijper, JC Lindsey, K Petrie, EC Schwalbe, K Barker, ...
Cancer cell 27 (1), 72-84, 2015
Regulation of transforming growth factor β1 by nitric oxide
Y Vodovotz, L Chesler, H Chong, SJ Kim, JT Simpson, W DeGraff, ...
Cancer research 59 (9), 2142-2149, 1999
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma
R Zeid, MA Lawlor, E Poon, JM Reyes, M Fulciniti, MA Lopez, TG Scott, ...
Nature genetics 50 (4), 515-523, 2018
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors
MW Richards, SG Burgess, E Poon, A Carstensen, M Eilers, L Chesler, ...
Proceedings of the National Academy of Sciences 113 (48), 13726-13731, 2016
New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK
G Barone, J Anderson, ADJ Pearson, K Petrie, L Chesler
Clinical Cancer Research 19 (21), 5814-5821, 2013
Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse.
Y Vodovotz, AG Geiser, L Chesler, JJ Letterio, A Campbell, MS Lucia, ...
The Journal of experimental medicine 183 (5), 2337-2342, 1996
Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium
JF Shern, J Selfe, E Izquierdo, R Patidar, HC Chou, YK Song, ME Yohe, ...
Journal of Clinical Oncology 39 (26), 2859, 2021
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity
L Fultang, S Booth, O Yogev, B Martins da Costa, V Tubb, S Panetti, ...
Blood, The Journal of the American Society of Hematology 136 (10), 1155-1160, 2020
Neuroblastoma arginase activity creates an immunosuppressive microenvironment that impairs autologous and engineered immunity
F Mussai, S Egan, S Hunter, H Webber, J Fisher, R Wheat, C McConville, ...
Cancer research 75 (15), 3043-3053, 2015
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
MI Walton, PD Eve, A Hayes, MR Valenti, AK De Haven Brandon, G Box, ...
Clinical Cancer Research 18 (20), 5650-5661, 2012
The system can't perform the operation now. Try again later.
Articles 1–20